Document is current
Any future updates will be listed below
-
Authors
Xie, Qing https://orcid.org/0000-0001-6253-1243
Chen, Xiupeng https://orcid.org/0000-0001-5916-3953
Ma, Hong
Zhu, Yunxiang
Ma, Yijie https://orcid.org/0000-0002-8750-8354
Jalinous, Leila
Cox, Gerald F
Weaver, Fiona
Yang, Jun
Kennedy, Zachary https://orcid.org/0000-0003-2476-1624
Gruntman, Alisha
Du, Ailing
Su, Qin
He, Ran
Tai, Phillip WL https://orcid.org/0000-0001-7409-8344
Gao, Guangping https://orcid.org/0000-0003-0097-9012
-
Funding
Funding for this research was provided by:
CANbridge Pharmaceuticals
- License Information
-
More Information
Article History
Received: 2 November 2023
Revised: 31 January 2024
Accepted: 1 February 2024
First Online: 27 February 2024
Disclosure and competing interests statement
: QX, HM, GG, and JX are inventors of a patent application filed by the University of Massachusetts Chan Medical School on SMA gene therapy. GG is a scientific co-founder of Voyager Therapeutics, Adrenas Therapeutics, AAVAA Therapeutics, and Aspa Therapeutics and holds equity in these companies. PT, GG, and JX are inventors of patents related to AAV-based gene therapy, some of which were licensed to commercial entities. YM, LJ, FW, JY, and ZK are employees of CANbridge Pharmaceuticals. YM, LJ, GC, JY, and ZK hold equity and/or stock options in CANbridge Pharmaceuticals. The other authors declare no competing interests.
